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Background: Cardiovascular diseases are the main cause of death worldwide, making their prevention a major
health care challenge. In 2006, a German statutory health insurance company presented a novel individualised
prevention programme (KardioPro), which focused on coronary heart disease (CHD) screening, risk factor
assessment, early detection and secondary prevention. This study evaluates KardioPro in CHD risk subgroups, and
analyses the cost-effectiveness of different individualised prevention strategies.
Methods: The CHD risk subgroups were assembled based on routine data from the statutory health insurance
company, making use of a quasi-beta regression model for risk prediction. The control group was selected via
propensity score matching based on logistic regression and an approximate nearest neighbour approach. The
main outcome was cost-effectiveness. Effectiveness was measured as event-free time, and events were defined
as myocardial infarction, stroke and death. Incremental cost-effectiveness ratios comparing participants with
non-participants were calculated for each subgroup. To assess the uncertainty of results, a bootstrapping approach
was applied.
Results: The cost-effectiveness of KardioPro in the group at high risk of CHD was €20,901 per event-free year; in
the medium-risk group, €52,323 per event-free year; in the low-risk group, €186,074 per event-free year; and in the
group with known CHD, €26,456 per event-free year. KardioPro was associated with a significant health gain but
also a significant cost increase. However, statistical significance could not be shown for all subgroups.
Conclusion: The cost-effectiveness of KardioPro differs substantially according to the group being targeted.
Depending on the willingness-to-pay, it may be reasonable to only offer KardioPro to patients at high risk of
further cardiovascular events. This high-risk group could be identified from routine statutory health insurance data.
However, the long-term consequences of KardioPro still need to be evaluated.
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Cardiovascular diseases (CVD) are the leading cause of
mortality in Germany and globally [1]. They are involved
in approximately 40% of all deaths before the age of
75 years in Europe [2]. Allthough CVD mortality has de-
creased considerably in recent decades in the United
States (US) and the European Union (EU), the burden is
still high [2,3]. According to the German Federal Office
of Statistics, CVD caused around 350,000 deaths in 2011,
and cost €37 billion in 2008 [4,5]. CVD are accountable
for 17% and 10% of total healthcare expenditure in the US
and the EU, respectively [3,6].
Prevention programmes include feasible and applicable
measures such as the use of evidence-based medical
therapies or reducing and controlling risk factors [2,3].
Reviews have shown that prevention programmes reduce
CVD risks, increase the quality of life of patients and im-
prove the health care provided [7,8]. Programmes which
help control risk factors may reduce coronary heart dis-
ease (CHD) mortality by up to 50% whilst improving
treatment can reduce CHD mortality by up to 40% [2].
In 2006, the German Siemens statutory health insur-
ance company ‘Siemens-Betriebskrankenkasse’ (SBK) in-
troduced a cardiovascular prevention programme called
‘KardioPro’. The goals of this programme are to promote
prevention, early detection and guideline-based treat-
ment of CVD. The main characteristics of KardioPro are
controlling risk factors, CHD risk screening, CHD diag-
nosis, guideline-based therapy and an increasing number
and frequency of follow-up visits with cardiologists as
well as a number of prevention activities offered to the par-
ticipants. In addition to the regular social health care ser-
vices offered in Germany, KardioPro includes the use of
computerised tomography determination of the calcium
score and also angiography (CTA) for early non-invasive
diagnosis of CHD. Furthermore, easy access to new treat-
ment measures such as advanced coronary stenting tech-
nologies and the implementation of an electronic health
record with easy access for the patient and the participat-
ing physicians was introduced [9].
The objective of this study was to evaluate the cost-
effectiveness of KardioPro. We also aimed to quantify
the cost-effectiveness of KardioPro in different CHD risk
groups. On this basis, efficient strategies for targeting
risk groups could be developed.
Methods
KardioPro
KardioPro is an individualised prevention programme,
which includes screening for CHD, risk factor assessment,
early detection and secondary prevention of CHD. Kardio-
Pro was first introduced in Munich and later in Coburg,
Berlin, Karlsruhe, Erlangen and North Rhine-Westphalia.
To enrol in KardioPro, participants needed to be at least45 years of age. Furthermore, CHD prevalent subjects of
any age were eligible for inclusion. All subjects who met
the enrolment criteria received information in writing
about KardioPro. Individuals in KardioPro were divided
into different pathways: patients known to have CHD, sus-
pected to have CHD and without CHD. Each pathway had
a different setting depending on the individual risk or the
severity of the disease. For risk assessment, the original
Prospective Cardiovascular Münster (PROCAM) score
was used [10]. This score defined the 10-year risk of
sudden cardiac death or a definite fatal or nonfatal myo-
cardial infarction and stratified diagnostic and therapeutic
strategies. Furthermore, all KardioPro participants were
categorised as either CHD prevalent subjects or subjects
with high, medium or low risk, according to the PRO-
CAM score.
The management plan for each individual patient was
provided by the participating cardiologists whose task was
to prescribe the optimal medical treatment for the patients
and to manage the risk factors according to European
guideline recommendations. Furthermore, KardioPro in-
cluded recent techniques such as CT for calcium scoring
(Agatston score) and/or CTA for diagnosis. In the case of
necessary coronary stenting advanced types of drug-eluting
stents were allowed. In addition, an electronic health rec-
ord was created offering easy access for patients and facili-
tating communication between specialists and institutes
participating in KardioPro. Patients were also sent re-
minders about follow-up visits.
Subgroups and control groups
For the evaluation of KardioPro, we included partici-
pants who enrolled 2007, 2008 and 2009 and ended the
observation at 31 December 2010. As the treatment paths
in KardioPro differed according to risk classification, the
cost-effectiveness of KardioPro was intended to be deter-
mined by risk group. However, the risk classification that
was applied to KardioPro participants was not suitable for
analysis, as risk classification was based on information
that has only been observed for participants. The applied
PROCAM score requires information about smoking be-
haviour, blood pressure and cholesterol level, which is not
included in German sickness funds routine data [10]. Ap-
plying propensity score matching to each of the KardioPro
risk groups would most likely have yielded biased control
groups (selection bias), as the outcome of KardioPro
depends on CHD risk. To achieve unbiased results, risk
group classification needed to be consistent between
KardioPro participants and controls. Furthermore, to
develop efficient strategies for targeting selected risk
groups (i.e. offering or advertising KardioPro to selected
individuals), the risk groups needed to be defined inde-
pendently from participation. Thus, for economic evalu-
ation, new groups of patients at risk of CHD were defined
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ever, our definition of risk groups was inspired by the risk
groups originally defined in KardioPro.
Firstly, we identified CHD prevalent subjects based on
administrative morbidity classification. This information
is included in routine data, as the presence of CHD has
to be reported for each insured person within the
German morbidity-based risk structure compensation
scheme. The remaining subjects were divided into sub-
jects with low, medium or high CHD risk. CHD risk
scores (such as the PROCAM or the Framingham score)
could not be calculated directly based on routine data.
However, the PROCAM score [10], which measures the
probability of CHD incidence within the next 10 years,
was available for KardioPro participants. Thus, we built a
regression model to predict the PROCAM score based on
routine data. The routine data from CHD non-prevalent
participants with a known PROCAM score at baseline of
KardioPro were used as input data. As the PROCAM
score is a probability and thus has a valid range from 0 to
1, we chose a quasi-beta regression model for prediction
[11]. The explanatory variables used for prediction were
age, sex, hypertension, obesity and diabetes, and referred
to the year prior to KardioPro participation. These vari-
ables were selected as they best corresponded to predic-
tion variables in the original PROCAM score [10]. As
data for three accounting years have been combined
within the regression model, we also included a random
intercept for the calendar year (2007, 2008 and 2009).
The concordance of the prediction model and the ori-
ginal PROCAM score was quantified via the Spearman’s
rank correlation coefficient. The threshold values to
define the low, medium and high CHD risk groups were
set in such a way that the same proportions were
achieved, as observed for the originally defined Kardio-
Pro risk groups (i.e. 9.72% high risk, 11.16% medium
risk and 79.12% low risk among non-CHD KardioPro
participants). All risk groups that we used for analysis
were built based on data collected prior to enrolment in
KardioPro. Thus the intervention did not affect the risk
group categorisation.
Control groups were created by retrospective propen-
sity score matching. All individuals insured by the health
insurance company who did not participate in KardioPro
were eligible as potential controls. However, as there are
severe regional differences regarding health expendi-
tures, only subjects from the regions where KardioPro
has been offered were considered as controls. Depend-
ing on the year of enrolment, the number of KardioPro
participants and potential controls were as follows:
2007: 2,953 new KardioPro participants, 131,109 poten-
tial controls, 2008 5,745 new KardioPro participants,
163,756 potential controls, 2009: 4,418 new KardioPro
participants, 180,612 potential controls.In our analysis, the propensity score was defined as the
probability of the individual participating in KardioPro.
The propensity score was computed by a logistic regres-
sion model based on the individual’s characteristics in the
previous year (one propensity score model per calendar
year). This model was selected from different logistic
regression models (backward and stepwise variable se-
lection and a full model) which were evaluated by cross-
validation. Stepwise variable selection was used in the
model and considered more than 140 potential explana-
tory variables (see Additional file 1 for a complete list of
all variables included). We used the approximate nearest
neighbour 1:1 without replacement approach by modify-
ing a published macro [12]. The matching macro started
to select pairs with an identical propensity score on the
10th decimal and decreased step by step until the first
decimal. An additional criterion was being insured for
the whole matching calendar year. Matching was done
separately for each subgroup and also by year 2007,
2008 and 2009.
Health and cost outcomes for the base case analysis
The primary health outcome was defined as event-free
time and measured by counting the days until the first
event (event-free days). The observation time for each
matched pair started from the enrolment date of the
participant in KardioPro. The observation time ended
for each individual either with the first event or by cen-
soring. Events were defined by a combined endpoint of
death (all causes), myocardial infarction (MI) and stroke.
MI and stroke were defined via the international classifi-
cation of diseases (ICD) codes in a hospital (i.e. acute
myocardial infarction (ICD-10, I21), subsequent myocar-
dial infarction (ICD-10, I22), cerebral infarction (ICD-
10, I63) and stroke (ICD-10, I64)). Censoring took place
at the end of the observation period (i.e. 31 December
2010). Furthermore, the observation time was censored
for both partners in a matched pair when either of them
cancelled their SBK health insurance. Therefore, differ-
ences in observed time were a result of events only.
As the health outcome was calculated on a daily basis,
daily health expenditures would have been desirable to
calculate incremental costs. However, the routine data
used for analysis reported costs for whole calendar years
only, thus guiding the presentation of results.
The considered costs for each matched pair were de-
fined as follows. For the year of enrolment, we assumed
that, on account of propensity score matching, the ex-
pected health expenditures prior to enrolment did not dif-
fer systematically between the participant and the control
subject. Thus, the costs for the whole calendar year were
considered for each partner. In the case of censoring as a
result of cancelling the SBK health insurance, which could
occur on any day within the calendar year, the total costs
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subject who (first) cancelled their SBK health insurance.
For the matched partner however, costs were only
accounted proportional to the time considered for the
evaluation. When a subject died, the total reported costs
of the follow-up period for both partners were consid-
ered. In cases of non-fatal events all subsequent costs
for both matching partners were considered.
All costs were inflated to the year 2010 based on infla-
tion rates provided by the German Federal Statistical Of-
fice [5]. Costs and effects were also discounted by using
an annual discount rate of 5% [13]. Furthermore, costs
were stratified into the following categories: hospital costs,
pharmaceutical costs, physician costs and other costs. The
category ‘other costs’ included, for example, physiother-
apy, laboratory resources, the costs of additional services
such as acupuncture and the cost of sickness benefits.Cost-effectiveness analysis
We assessed the cost-effectiveness of KardioPro from
the statutory health insurance (SHI) perspective. TheTable 1 The base case analysis for all the strategies with ‘day




















































2,693 605.44 597.93 7.51
(3.45) (3.55) (2.28)
*Only the difference in costs between intervention and control group are displayed
CHD: coronary heart diseases.
ICER: incremental cost-effectiveness ratio.
SE: standard error.
Costs were inflated to the year 2010. Both costs and effects were discounted at 5%incremental cost-effectiveness ratio (ICER = (cost of inter-
vention–cost of control)/(effect of intervention–effect of
control)) was determined for KardioPro as a whole and
for the individual risk groups. To illustrate which strat-
egies are efficient, if KardioPro were to be offered to
selected risk groups, we also considered combined strat-
egies, i.e. offering KardioPro to more than one risk
group simultaneously. This resulted in eight strategies
overall (these are explicitly listed in Table 1). These
combined strategies were graphically represented via an
efficiency frontier [14,15].Secondary health outcome, sensitivity analyses and
uncertainty assessment
Based on the number of days until death, a secondary
health outcome analysis was conducted. The discount
rate has been varied (at 0%, 3% and 10%) via determinis-
tic sensitivity analysis [13]. Finally, to derive standard er-
rors, we performed a bootstrapping approach for all the
strategies by drawing 10,000 samples with replacement




















41,514 674.35 8,842,036 77,742
(11,070) (133.82) (1,754,657)
9,226 473.92 668,696 26,456
(6,238) (607.67) (857,428)
10,182 604.79 583,014 20,901
(4,136) (555.02) (535,035)
10,041 832.47 1,439,334 52,323
(4,537) (425.73) (736,090)
12,066 682.84 6,150,992 186,074
(6,694) (138.69) (1,249,335)
29,558 655.71 2,690,846 33,251
(8,761) (304.32) (1,261,563)
19,344 527.04 1,254,061 23,678
(7,501) (425.34) (1,000,480)
20,241 750.96 2,016,933 36,395
(6,019) (337.36) (910,159)
, as the absolute values are confidential.
.
Table 3 Quasi-beta regression with logit link function to
predict the PROCAM coronary artery disease risk based
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package SAS, version 9.2.on sickness funds’ routine data
Parameter Estimate Standard
error
DF t statistic p value
Intercept −1.1952 0.254 2 −4.59 0.04
Age 0.0472 0.005 1223 9.02 <0.0001
Gender (female) −0.8587 0.103 1223 −8.31 <0.0001
Diabetes 0.0513 0.394 1223 0.12 0.91
Hypertension 0.0908 0.099 1223 0.87 0.39
Obesity 0.4230 0.124 1223 3.55 0.0004
DF: degrees of freedom.Ethics
The aim of this study was to evaluate the real-world health
care programme KardioPro. The intervention KardioPro
was offered to all persons insured by SBK as part of the
health care basket provided by a German statutory health
insurer, and is covered by the German Social Code §§97,
80 SGB X and §§67, 43 SGB V. KardioPro did not intro-
duce new treatment methods, but worked by strengthen-
ing guideline-specific treatment. This type of support falls
within the common responsibilities of a statutory health
insurance company. Only subjects who gave written con-
sent to participation were included in KardioPro. Evalu-
ation of KardioPro was authorised by SBK, designed
retrospectively and commissioned to an independent re-
search group. The evaluation was based on anonymised,
patient-specific routine data from SBK and was approved
by the SBK data protection officer.Results
In the years 2007, 2008 and 2009 (the enrolment period),
13,116 individuals participated in ‘KardioPro’. For four
of them, no matching control with a similar propensity
score was found. After propensity score matching, 26,224
individuals (13,112 matched pairs) entered our analysis.
The average age was 59.2 years for ‘KardioPro’ partici-
pants and 59.4 years for the control group. Females
accounted for 45.4% of the participants and 45.8% of the
control group. Differences in arterial hypertension and
other co-morbidities between the two groups are shown
in Table 2. For the risk level model (Table 3), the Spear-
man rank correlation coefficient between the originally
measured PROCAM scores and the corresponding pre-
dicted risk level values was 0.74, which was highly signifi-
cant (p < 0.0001).Table 2 The baseline characteristics of the population of
the KardioPro study
Criteria KardioPro participants Control subjects
Female (%) 5,950 (45.4%) 6,004 (45.8%)
Age (years)
- Mean (SD) 59.17 (8.7) 59.42 (8.7)
- Range 39–88 39–94
Arterial Hypertension (%) 3,984 (30.4%) 4,075 (31.1%)
Diabetes mellitus (%) 1,537 (11.7%) 1,553 (11.8%)
Obesity (%) 1,665 (12.7%) 1,694 (12.9%)
History of stroke (%) 29 (0.2%) 17 (0.1%)
Total 13,112 13,112
SD: standard deviation.The mean observation time in the intervention and
control group was 2.39 years and 2.38 years, respectively.
There were 120 (0.92%) deaths, 105 (0.80%) subjects who
experienced MI and 79 (0.60%) subjects who experienced
stroke in the KardioPro group, whereas in the control
group there were 219 (1.67%) deaths, 114 (0.87%) subjects
who experienced MI and 83 (0.63%) subjects who experi-
enced stroke. KardioPro as a whole was associated with a
statistically significant health gain (3.2 event-free days per
participant, 95% confidence interval (CI) [1.7, 5.0], p =
0.0002) and a significant cost increase (€674.35 per partici-
pant, 95% CI [€438, €961], p < 0.0001). The overall cost-
effectiveness of KardioPro was €77,742 (95% CI [€32,295,
€260,147]) per event-free year.
Among the individual risk groups and combined strat-
egies (Table 1), the gain of event-free days was highest in
high CHD risk subjects (10.56 days SE 4.31) and lowest in
low CHD risk subjects (1.34 days SE 0.74). The highest
additional costs were observed within the median CHD
risk subjects (832.47€ SE 420.84) and the lowest additional
costs within the CHD prevalent subjects (473.92€ SE
607.50). These differences yielded a wide range of cost-
effectiveness ratios, ranging from €20,901 (high CHD risk)
to €186,074 (low CHD risk) per event-free year (no CIs re-
ported, as points are scattered over multiple quadrants of
the cost-effectiveness plane). Six of the eight examined
strategies offering KardioPro to selected risk groups were
effective in increasing event-free days (‘KardioPro for all’
p < 0.0001, ‘KardioPro for CHD prevalent subjects and
medium and high CHD risk subjects’ p = 0.0006, ‘for high
CHD risk and CHD prevalent subjects’ p = 0.0110, ‘for
high CHD risk subjects’ p = 0.0120, ‘for medium and high
CHD risk subjects’ p = 0.0004 and ‘for medium CHD risk
subjects’ p = 0.0286). Four of the strategies caused sig-
nificantly higher costs (KardioPro for all’ p < 0.0001,
‘KardioPro for CHD prevalent subjects and medium and
high CHD risk subjects’ p = 0.0312, ‘KardioPro for medium
and high CHD risk subjects’ p = 0.0276 and ‘for low CHD
risk’ p < 0.0001).
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prevalent subjects’ was dominated, even though only
slightly and without statistical significance, by ‘KardioPro
for high risk and CHD prevalent subjects’ (see efficiency
frontier, Figure 1). However, when the health outcome
‘time until death’ was used, the strategy ‘KardioPro for
CHD prevalent subjects’ dominated the strategy of
‘KardioPro for high risk subjects’ (Figure 2, still only
slightly and without statistical significance). A colour
cost-effectiveness scatterplot based on bootstrapping for
targeting the individual risk groups and KardioPro as a
whole is supplied in Figure 3. A corresponding plot for
all strategies that build the efficiency frontier can be
found in the Additional file 2.
Among the single cost categories, physician costs con-
tributed most to the incremental costs (Table 4). In con-
trast to physician costs, hospital costs were associated
with cost savings due to KardioPro. The effect of the dis-
count rate on the ICER was negligible (Additional file 3).
Discussion
In this study, we evaluated the cost-effectiveness of the
cardiovascular prevention programme KardioPro as a
whole as well as in terms of strategies focused on selected
subgroups of risk. As these subgroups were based on rou-
tine data, health insurance companies can easily select
these risk groups for future enrolment. For rational deci-
sion makers, we also identified targeting strategies. Which
of these strategies can be accepted as efficient and should
be chosen, however, depends on the willingness-to-pay.
This is not the first cost-effectiveness analysis of a multi-
intervention programme to prevent CVD. Field et al.,Figure 1 The base case strategies with ‘days until the first event’ (my
cost until death in the cost-effectiveness plane with the expansion pa
discounted at 5%. All: KardioPro for all risk groups. CHD: KardioPro for coro
Medium: KardioPro for medium-risk group. Low: KardioPro for low-risk grou
patients groups. Middle, high and CHD: KardioPro for middle-risk, high-risk
KardioPro for middle-risk and high-risk groups. None: KardioPro for none.for example, examined the cost-effectiveness of a range
of prevention strategies, including several screening strat-
egies and lipid lowering drugs [16]. Several disease man-
agement and health promotion bonus programmes
initiated by German health insurance companies have
been analysed previously [17-20]. These evaluations were
also based on routine data. Yet, as subgroup analyses were
not included, a special aspect about our study is that we
inform decision makers on the cost-effectiveness of differ-
ent individualized CHD prevention strategies.
The effectiveness and the cost-effectiveness of Kardio-
Pro differed substantially regarding the subgroups con-
sidered in our analysis. Both the effectiveness and the
cost-effectiveness were most favourable in high CHD
risk and CHD prevalent subjects. However, the order of
cost-effectiveness among these two subgroups varied
within sensitivity analyses. Nevertheless, our analysis has
shown that the health effect is higher and the cost-
effectiveness is more favourable in subgroups at high car-
diovascular baseline risk. This association has also been
observed previously, for example by Field et al. [16]. In
addition it has to be kept in mind, that the effect of Kar-
dioPro was relatively small (days free of event per person
between 1.34 to 10.56) during the mean observation
period of 2.4 years.
The clinical effectiveness in our study was based on
the combined endpoint of stroke, MI and all-cause mor-
tality. One may wonder, why we did not refer to cardio-
vascular mortality, but included mortality of any cause
instead. This was done for two reasons. Firstly, cause of
death is not reported within health insurance company
routine data. Secondly, even if we would have been ableocardial infarction, stroke or death) as the health outcome and
th. Costs were inflated to the year 2010. Both costs and effects were
nary heart disease patients group. High: KardioPro for high-risk group.
p. High and CHD: KardioPro for high-risk and coronary heart disease
and coronary heart disease patients groups. Middle and high:
Figure 2 The strategies with the secondary health outcome ‘days until death’ and cost until death in the cost-effectiveness plane with
the expansion path. Costs were inflated to the year 2010. Both costs and effects were discounted at 5%. All: KardioPro for all risk groups. CHD:
KardioPro for coronary heart disease patients group. High: KardioPro for high-risk group. Medium: KardioPro for medium-risk group. Low:
KardioPro for low-risk group. High and CHD: KardioPro for high-risk and coronary heart disease patients groups. Middle, high and CHD: KardioPro
for middle-risk, high-risk and coronary heart disease patients groups. Middle and high: KardioPro for middle-risk and high-risk groups. None:
KardioPro for none.
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certificates, this information would not have been
suitable for analysis. Death certificates in Germany are
known to have a high proportion of misclassification
[21]. A priori we assumed that cardiovascular events, in-
cluding cardiovascular mortality, were likely to be iden-
tified in KardioPro participants more frequently. To
avoid bias, the ‘hard’ endpoint ‘all-cause mortality, MI
and stroke’ has been applied.Figure 3 Plot of 10,000 bootstrap samples for each strategy in the co
each. All: KardioPro for all risk groups. CHD: KardioPro for coronary heart d
KardioPro for medium-risk group. Low: KardioPro for low-risk group.Furthermore, it would have been valuable to distinguish,
which costs do and which do not refer to cardiovascular
interventions and procedures. However, the reported cost
categories were selected a priori, were approved by the
SBK data protection officer, and could not be further dis-
aggregated in later stages of the evaluation process.
To a large extent, the health effect of KardioPro results
from improvements in early diagnosis and treatment.
These could be achieved through the leading role ofst-effectiveness plane with 95% confidence interval ellipsoids for
isease patients group. High: KardioPro for high-risk group. Medium:




















8.84 −1.63 9.14 −0.86 2.18
(1.75) (1.25) (0.29) (0.88) (0.70)
Mean difference per
pair in € (SE)
674.35 −124.67 697.08 −65.51 253.13






0.67 −0.33 1.7 −0.41 −0.28
(0.86) (0.73) (0.11) (0.31) (0.37)
Mean difference per
pair in € (SE)
473.92 −234.95 1,205.13 −287.29 38.88






0.58 −0.74 0.97 0.13 0.22
(0.54) (0.41) (0.08) (0.16) (0.24)
Mean difference per
pair in € (SE)
604.79 −768.09 1,005.87 135.68 57.04






1.44 −0.27 1.38 −0.34 0.66
(0.73) (0.54) (0.09) (0.33) (0.25)
Mean difference per
pair in € (SE)
832.47 −153.44 799.42 −199.39 799.42






6.15 −0.29 5.09 −0.24 1.59
(1.21) (0.75) (0.23) (0.74) (0.48)
Mean difference per
pair in € (SE)
682.84 −33.01 564.81 −26.60 564.81
(137.43) (86.76) (25.14) (80.98) (25.14)
*Other costs include costs for any other health services such as physiotherapy or laboratory services, costs for additional services such as acupuncture and also
the costs of sickness benefits.
CHD: coronary heart diseases.
SE: standard error.
Costs were inflated to the year 2010 and discounted at 5%.
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only been shown to be more effective in the treatment
of coronary patients, compared with general practitioners
and internists [22,23], they have also been advised to pre-
cisely follow evidence-based treatment guidelines, which
are currently not followed sufficiently in Germany [24].
This may explain the strong health effect in subgroups at
high cardiovascular baseline risk. The increase in phys-
ician costs can also be explained by the high involvement
of cardiologists. The decrease in hospital costs and costs
related to medical drugs, in contrast, might have re-
sulted from avoided cardiovascular events. However, we
point out that the cost data provided for analysis was
not event-specific.
We would like to stress that the time horizon of our
study is relatively short. As KardioPro includes several pre-
ventive measures, the incidence of cardiovascular events is
also likely to differ beyond the follow-up period. Even the
costs and consequences of the events that have beenobserved within the follow-up period are not captured
totally. Cardiovascular events are associated with long-
term consequences, as they can reduce longevity and
may cause or prevent future costs. Thus, it is possible
that the cost-effectiveness ratios would change over
time. However, there is a direct trade-off between the
choice of a lifetime study horizon in the analysis of rou-
tine data and the opportunity to make timely decisions
about prevention programmes including current treat-
ment technologies.
Another limitation of our study is that it is based on ob-
servational data and not on a randomised controlled trial
[25,26]. Although the propensity score matching helped to
create a comparable control group, matching can only
control for observed variables and thus bias can still re-
main [27]. For example, behavioural characteristics such
as smoking, diet or exercise were not covered by the data-
base. The same is true for some medical conditions such
as gout or renal failure.
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http://www.biomedcentral.com/1472-6963/14/263An important aspect to highlight is that we aimed to
create risk groups based on routine data. The PROCAM
score could not be calculated directly based on the rou-
tine data, as required variables, such as smoking behav-
iour, blood pressure and cholesterol level, were missing.
Therefore, we created a prediction model based on the
PROCAM score that was reported for participants. The
PROCAM score was originally only defined for males and
a certain age range [10], however, it has been applied in
KardioPro as a risk indicator for women and subjects of
different ages. For our economic evaluation, we were not
interested in accurate estimates of the 10-year cardiovas-
cular risk but in defining risk groups. Both the Spearman
rank coefficient and our results suggest that the risk strati-
fication was successful. However, it is conceivable that a
better risk stratification could be derived from health in-
surance company routine data. Therefore, we recommend
further research.
Regarding the health outcome, censored data such as
ours are often analysed via Kaplan–Meier curves or Cox
regression models. However, this was not possible given
the study objective: cost-effectiveness analyses require
the quantification of both costs and effects. The study
design that we chose has been selected to minimise bias
for the given time horizon. This has been in accordance
with the analysis of censored cost data [28].Conclusion
In conclusion, the cost-effectiveness of KardioPro differs
greatly according to the group being targeted. Subjects
at high risk of CHD and with known CHD appear to be
the groups that benefit most from KardioPro. Depending
on the willingness-to-pay, it may be reasonable to only
offer KardioPro to patients at high risk of future cardio-
vascular events. This high-risk group could be identified
based on health insurance company routine data. How-
ever, the long-term consequences of KardioPro still need
to be evaluated.Additional files
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explanatory variables within the logistic regression model.
Additional file 2: Scatterplots on the cost effectiveness plane.
Additional file 3: The incremental cost-effectiveness ratio for
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